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22 Abstract:
23 This position paper highlights the opportunistic integral role of the pharmacist across 
24 the patient pathway utilising cardiovascular care as an example.  The paper aims to 
25 highlight the potential roles that pharmacists worldwide can have (or already have) to 
26 provide efficient patient care in the context of interprofessional collaboration. It 
27 results from a literature review and experts seeking advice to identify existing 
28 interventions and potential innovative interventions. We developed a conceptual 
29 framework highlighting seven critical phases in the patient pathway and for each of 
30 those listed some of the initiatives identified by our experts worldwide. Based on the 
31 findings, we can argue that much has been done but globally consider that 
32 pharmacists are still an untapped resource potentially useful for improved patient 
33 care.
34 Keywords: Cardiovascular Diseases, Anticoagulants, Pharmacists, Interprofessional 
35 Relations, Comprehensive Health Care
36
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38 The patient pathway in cardiovascular care: a position paper from the 
39 International Pharmacists for Anticoagulation Care Taskforce (iPACT)
40 Running title: Patient pathway in cardiovascular care
41 Background: The European Heart Rhythm Association (EHRA) White Book is a 
42 resource containing extensive information on the status of care provided to cardiac 
43 arrhythmia patients in European countries. Some of the information included in this 
44 resource mentions the extent of implementation of guidelines in the respective 
45 countries. It is a useful resource to annually monitor changes in patient care. 
46 However, most of the information here contained is physician-led, therefore 
47 information on important interventions provided by other health care professionals, or 
48 even by informal carers, for better patient care are missing (1).
49 The EHRA Guide on the use of non-vitamin K antagonist anticoagulants in patients 
50 with non-valvular atrial fibrillation (AF) defined 15 topics that need to be considered 
51 for using these drugs effectively and safely in clinical practice. Some of them include 
52 initiation of therapy and subsequent monitoring and ensuring of adherence. This 
53 document also recommends the use of specific tools, such as the warfarin alert card or 
54 the patient card for Non-vitamin K oral anticoagulants (NOACs) as a means to 
55 empower the patient in self-management (2).
56 The ESC guidelines are a set of recommendations advising health care professionals 
57 on how to provide high standard patient care in the various phases of a patient’s 
58 pathway. These exist for several areas, comprising lipid management, management of 
59 atrial fibrillation, to name a few. The recommendations included are anchored to a 
60 grading system that informs the reader on the source used to generate the 
61 recommendation and the attached classification for evidence generation (e.g. meta-
62 analysis versus expert opinion). Taking the latter as an example, opportunistic 
63 screening of AF is now recommended to be undertaken by pulse palpation or ECG 
64 rhythm strip, graded as class I, level B (3). In this same guideline, integrated 
65 management of patients is highlighted, where the person living with illness is seen as 
66 having a central role in the care process. This is a very important step forward, aside 
67 with the recognition that adequate detection should be made at the first point of care 
68 with the healthcare system, clearly recognised as most often being the pharmacist, the 
69 primary care physician or the community health worker. However, it should be 
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70 acknowledged that guidelines do not often get implemented into practice because the 
71 health care system structure and functioning is not considered, arguably due to the 
72 complexity of healthcare delivery and variability amongst countries. In most 
73 European countries, there are insufficient physicians in primary care for timely and 
74 adequate patient detection and monitoring (4). The implications are that in real life, 
75 the time available for medical appointment is clearly insufficient for patient 
76 education, encouragement and empowerment for self-management, for providing 
77 advice and education on lifestyle and risk factor management and ultimately for 
78 shared decision making (5). The guideline also remarks as a recommendation “An 
79 integrated approach with structured organization of care and follow-up should be 
80 considered in all patients with AF, aiming to improve guideline adherence and to 
81 reduce hospitalizations and mortality”, classified as class IIa, level B.
82 In addition, thinking of the individual’s perspective, a patient expectations’ and needs 
83 are different and often changes in time due to ageing, deterioration of the disease or 
84 comorbidities. Therefore, a person cannot be treated as a recipient of various diseases 
85 or disease situations and must instead be seen holistically and continuously. 
86 For all these reasons, it is important to consider in each country, which health care 
87 professionals are competent, well placed and the most readily accessible in delivering 
88 the various steps and subsequently translate guidelines into practice. Pharmacists 
89 seem to be the silent or an unnoticed profession, despite the fact that they are a highly 
90 regarded profession by both the World Health Organization (WHO) and patients (6). 
91 The European Pharmacists Forum has highlighted that community pharmacies are the 
92 most accessible healthcare locations (7). Indeed, in most countries of the world 
93 pharmacies are spread out geographically favouring community access. Additionally, 
94 in most of these countries, citizens do not need to book appointments to see their 
95 pharmacist or even pay to seek their professional advice. This is particularly 
96 important in the context of public health initiatives, particularly in the area of disease 
97 prevention, where a key to success is accessibility and gratuity. International 
98 Pharmacists for Anticoagulation Care Taskforce (iPACT) believes it is time to 
99 disseminate an overarching strategy paper for pharmacists intervening on patients 
100 across their lifetime pathway, using cardiovascular disease as an example. 
101 Aim: This position paper aims to highlight the potential roles within the patients’ 
102 pathway that pharmacists worldwide can intervene to provide efficient patient care in 
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103 the context of interprofessional collaboration. This will be done using cardiovascular 
104 disease, particularly atrial fibrillation (AF), as an example. The ultimate aim is to 
105 raise awareness, within and beyond the profession, about the pharmacist as an 
106 essential partner for better patient care. 
107 Methods: 
108 This position paper was developed by first mapping the pathway through which a 
109 person becomes a patient. This exercise was developed using a selected expert panel 
110 (SA, SR and FAC) with experience in hospital, ambulatory, and palliative care who 
111 tried to describe graphically this pathway. Subsequently, the panel used 
112 cardiovascular disease to populate the sections of the pathway, mainly consisting of 
113 the development of high risk characteristics, moving to medical diagnosis initiating 
114 treatment and safe-guarding it and then potentially progressing into palliative care. 
115 The third step consisted of a narrative literature review seeking to identify 
116 experiences along this pathway where interventions involving pharmacists had been 
117 developed, regardless of the level of differentiation or evidence gathered. This 
118 information was additionally supplemented with searches in the grey literature, 
119 mostly published and unpublished documents from pharmacists’ organisations, like 
120 the Pharmaceutical Group of the European Union (PGEU), the European Pharmacists 
121 Forum, the International Pharmaceutical Federation (FIP) and also national 
122 associations of iPACT members’ respective countries.
123 Finally, a larger expert panel (iPACT network, which involves expert pharmacists and 
124 patient advocates from over 25 countries) was sought to brain storm interventions that 
125 highlight opportunities for pharmacists to contribute, such as with the use of 
126 innovative technology in point of care testing. In all areas of the patient pathway, 
127 iPACT members were used to collect information on pharmacist-led services in their 
128 respective countries. All actual and potential interventions are highlighted throughout 
129 this pathway, which focuses mainly on primary prevention. Actual interventions 
130 reflect the current model of practice for community pharmacy, mainly identified 
131 through the literature review (which also included grey literature), while potential 
132 interventions reflect innovative experiences for which preliminary results (often only 
133 piloted and frequently not yet published) seem promising enough to be adapted 
134 elsewhere. 
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135 Results: Using pharmacies to identify patients at risk of a certain condition may be an 
136 effective way to develop efficient interventions, including early institution of therapy. 
137 These interventions may also include the promotion of healthy behaviours, namely 
138 through smoking cessation campaigns and immunisation strategies (8) (9). Using 
139 group discussions and consensus seeking methods, we have developed a conceptual 
140 model that describes the patient pathway in anticoagulation care (figure 1).
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146 The seven sequential steps highlighted in this diagram will be subsequently detailed 
147 and enriched with selected examples collected worldwide.
148
149 1 - Prevention and self-management 
150 Strokes may be preventable by modifying or treating the risk factors. As such, regular 
151 evaluation and management of modifiable risk factors is instrumental in disease 
152 prevention. Specific interventions in this area include risk stratification for 
153 cardiovascular disease and blood pressure and lipid management, to name a few. 
154 Health promotion and prevention activities also include disease awareness campaigns 
155 and healthy behaviour advice, where a good example of the latter is the smoking 
156 cessation service, available in primary care in various locations and delivered through 
157 the intervention of various professionals, depending on the country, namely family 
158 physicians, psychologists, nurses and pharmacists.
159 In England, roughly 20% of pharmacies provide smoking cessation service on a 
160 regular basis, reaching nearly 150,000 smokers a year. In Scotland, since the 
161 widespread implementation of smoking cessation service in 2008, pharmacies now 
162 provide 75% of all quit attempts. Wales and Northern Ireland provide similar services 
163 (10) (11). In Canada, smoking cessation is also a major task of pharmacists since the 
164 launch of the “Pharmacists for smoke free Canada” (12). 
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165 These services have been spreading as a result from earlier demonstration that 
166 pharmacists can competently deliver tobacco-cessation interventions (13). Reviews of 
167 pharmacists interventions in public health have concluded they are effective in 
168 regards to smoking cessation, although evidence is still lacking in other areas of 
169 behaviour change such as alcohol cessation or weight loss (14). Robust trial designs 
170 also led to the demonstration of the associated effectiveness of the service (15). 
171 Currently in England this commissioned service is being evaluated for its cost-
172 effectiveness through the use of a pragmatic trial conducted in 60 pharmacies; the 
173 service investigated is named “Smoking Treatment Optimisation in Pharmacies 
174 (STOP)” and is being compared with the standard smoking cessation service (16). 
175 Tobacco is a well-recognised modifiable risk factor for stroke and smoking cessation 
176 is regarded as a cornerstone of recurrent stroke prevention (17). So, even if there are 
177 is no evidence on the direct impact of pharmacist-led smoking cessation interventions 
178 in stroke reduction, the indirect impact seems quite obvious. 
179 A national Know your heart campaign was ran in half the pharmacies of Portugal, 
180 where 12,930 patients had blood pressure, body mass index, waist circumference and 
181 total cholesterol measured. This campaign allowed the detection of already diagnosed 
182 condition and receiving medication but with their condition uncontrolled. A total of 
183 5,600 patients were on antihypertensive medication and 4,700 on lipid lowering 
184 medication. The identification of patients with suboptimal therapy occurred in 50% 
185 and 53% of individuals in both these groups, respectively. Pharmacists referred 21% 
186 of patients to the physician, resulting in the initiation of new therapy in nearly half of 
187 them (18).
188  
189 2 - Identification of High risk patients through screening 
190 AF is responsible for a third of strokes and people with AF have a five-fold more risk 
191 of stroke. The 2016 ESC guidelines state opportunistic screening for AF is 
192 recommended by pulse taking or ECG rhythm strip in patients >65 years of age, a 
193 recommendation classified as class I (evidence or general agreement that a given 
194 treatment or procedure is beneficial, useful and effective) level B evidence (i.e. data 
195 derived from a single clinical trial or large non-randomised studies). Registry data 
196 suggests there are a high proportion of undiagnosed patients (19). An important factor 
197 contributing to this is the fact that a high proportion of individuals with AF are 
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198 asymptomatic. The literature on alternative venues for AF screening has been quickly 
199 progressing.  Traditionally, such events were held in GP practices, but recently the 
200 use of immunisation clinics, nurse-led clinics and community pharmacies has 
201 demonstrated added-value in the identification of additional suspects (20) (21) (22). 
202 Pulse palpation is the easiest way and is not part of routine clinical practice (23). 
203 Studies have highlighted community pharmacies as ideal partners due to their 
204 privileged location in the health care system and their easy access, provided 
205 adequately trained to undertake this activity. In fact, iPACT in partnership with A-
206 A/AFA has contributed to scale-up pharmacist-led awareness events where pulse 
207 palpation, in some cases allied with mobile ECG, is regularly organised in pharmacies 
208 around the world (24) (25). Innovative technologies have also been described as a 
209 means to increase other allied professionals ability to engage in detection and 
210 confidently refer onward to physicians (22) (21). The AF-screen international 
211 collaboration has recognised this and extended their collaboration to include allied 
212 professionals, namely nurses, pharmacists and patient advocates (26). The benefits of 
213 early detection of AF enable early institution of therapy and subsequent reduction in 
214 their risk of stroke; moreover, it may also be useful to identify diagnosed patients who 
215 are not treated or who are sub optimally treated with antiplatelet therapy instead of 
216 anticoagulation. 
217
218 3 - Appropriate and timely diagnosis 
219 When patients are timely diagnosed, therapy can be initiated early and additional 
220 benefits may be gained. In most countries, only physicians’ can prescribe but different 
221 models of pharmacists prescribing have been described internationally (27). In some 
222 countries (e.g. UK, Canada, USA) pharmacists may independently prescribe, although 
223 with varying levels of restrictions, implying therapy may be initiated by the 
224 pharmacist overcoming the need to refer, further reducing the workload of primary 
225 care clinicians. This implies that screening in areas where there are independent 
226 pharmacist prescribers, for who advanced competence pharmacotherapy levels are 
227 required, could potentially lead to higher detection rates but above all to a higher 
228 proportion of individuals correctly initiated on therapy by pharmacists in a timely 
229 manner. The challenges associated with this practice vary between and within 
230 countries and in some settings, the absence of important information, such as 
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231 laboratory data, may restrict the scope of practice. In the UK for instance, prescribing 
232 pharmacists may work in hospital, GP practices and in community pharmacies, where 
233 the availability of information varies and leads to differential models of collaborative 
234 practice, often including physicians and nurses. In all countries, however, the 
235 competency is well-established and supported by appropriate education and training. 
236 In countries where the activity of the pharmacist (or nurse) is dependent on the 
237 physicians, an efficient referral pathway must be in place so that individuals are not 
238 left on their own to take the decision to seek a physician appointment or simply to 
239 ignore the pharmacist’s advice. The current ESC guideline states that oral 
240 anticoagulation therapy to prevent thromboembolism and stroke is recommended for 
241 all AF patients with a CHA2DS2-VASc score of 2 or more (class I, level A).3 Studies 
242 have shown that when there is early detection, there is the additional opportunity to 
243 identify patients meeting these criteria who have been previously diagnosed but yet 
244 have not initiated anticoagulant therapy, designated as ‘actionable AF’ (28).
245 Even though the market share of NOACs has been progressively increasing 
246 worldwide, there are still many countries where VKAs lead the market. The ESC 
247 guideline states that when patients are treated with a vitamin K antagonist, time in 
248 therapeutic range (TTR) should be kept as high as possible and closely monitored 
249 (class I, level A). This implies INR needs to be regularly monitored. However, 
250 worldwide there are barriers for timely monitoring, so different solutions are 
251 necessary for different health care systems. AF patients already on a vitamin K 
252 antagonist may be considered for NOAC treatment if TTR is not well controlled 
253 despite good adherence, or if the patient expresses his preference and has no contra-
254 indications to NOAC (e.g. prosthetic valve) (class IIB (usefulness/efficacy is less well 
255 established by evidence/opinion), level A). This implies that adherence is monitored 
256 and subsequently enabling strategies are developed.
257 In some countries, INR monitoring is exclusively done in hospital, whereas in others 
258 it may be done in primary care. Within primary care, there are also varied solutions 
259 that may include the local health care centre, laboratories or pharmacies. Portugal is 
260 an example where there was an unmet need in primary care, conditioned by 
261 availability and affordability of structures in place, which led to pharmacies to start 
262 providing this service. Although it is still currently only available in around 5% of the 
263 pharmacies, it has been quickly growing (29).
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264 Adherence encompasses two aspects: a) adherence of healthcare professionals to 
265 guidelines and b) adherence of patients to therapy. The first of these will be dealt in 
266 this section as we consider it arises immediately upon diagnosis. Patient’s medication 
267 adherence will be dealt in a different section as it may occur in various phases (see 
268 section 5). 
269 3.a) Adherence of healthcare professionals to guidelines: 
270 The evidence suggests the proportion of patients prescribed according to guidelines is 
271 suboptimal (30). Up to 25% of patients who are hospitalized and up to one third of 
272 ambulatory patients receive an inappropriate dose of DOAC (31) (32). It has been 
273 shown that only certain risk criteria justify dose reduction (e.g. renal impairment) 
274 (33). Under dosing with no renal indication resulted in a nearly five-fold increased 
275 risk of stroke without significant difference in major bleeding. Conversely, 
276 overdosing in renal impairment doubled the bleeding risk but had no impact on stroke 
277 occurrence. (34)
278 NOAC are most commonly used in lower doses, compared to higher doses (35), 
279 perhaps suggesting prescribers tend to be overcautious due to potential adverse drug 
280 events or eventually as an indirect result of not having as easy and common 
281 laboratory data as when prescribing VKAs. 
282 Predictors for inappropriate dosing vary between studies, but in general the 
283 phenomena occurs with all NOACs, whereas decreased renal function is most 
284 commonly described as associated with prescribing errors (35). Off label dosing of 
285 NOACs has also been described as more common among the elderly, those with 
286 higher bleeding and stroke risks (36). This suggests that pharmacists engaging in 
287 medication review could focus on dose appropriateness for this specific class. Some 
288 have suggested multidisciplinary clinics as a means to ensure safe and effective 
289 prescribing and follow-up (35). Within hospital, clinical pharmacists have 
290 successfully intervened in patients on inappropriate NOACs prescriptions, either 
291 suggesting dose adaption, avoidance of interacting drugs, the need for NOAC 
292 monitoring, to name a few, 70% of which accepted by the physician (37). Also in the 
293 US, the emergence of pharmacist-led NOAC management services is currently a 
294 solution to reduce the risk of incorrect dosing in this class, not only within hospital 
295 but also across the healthcare system (38). In some countries, pharmacist-led services 
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296 for optimising medicines use have emerged also in the ambulatory setting, namely the 
297 polymedication check in Switzerland (39), the New Medicines Service in the UK (40) 
298 or the Chat Check Chart in Canada (41). In Belgium for instance, there’s a 
299 government funded quality improvement program around the safe use of NOAC, 
300 focusing on the right dose for the right patient. Within this program, local physicians’ 
301 and pharmacists can discuss cases, analyse their current prescribing and dispensing 
302 profile and advise dose changings (42).
303 Choosing the right therapy may be quite complex and various studies have 
304 highlighted that inappropriate medications are frequently overprescribed and that 
305 pharmacists engaging in various forms of medication review have a key role in 
306 minimising the problem (43).
307
308 4 - Integrated care ensuring multiprofessional collaboration
309 One recommendation that is consistent in every guideline is that AF patients on OAC 
310 therapy should receive an integrated approach, with structured personalized care and 
311 follow-up. In many countries, if not in the majority, this aspect may be considered as 
312 the major flaw of the healthcare system. There are anecdotal descriptions of lack of 
313 integrated care where citizens receive defragmented advice from various providers, 
314 sometimes inconsistent, and also where there is no appropriate means created for data 
315 sharing or information flow (44). The consequences are immense, not only for the 
316 system, where often duplicate diagnostic tests may occur, leading to avoidable costs, 
317 but also for the individual, who finds himself lost in an intricate and siloed health 
318 system, where barriers are profuse. For the individual in particular, the consequences 
319 may include contradicting information about diagnosis, duplicate diagnostic testing, 
320 or interacting therapy leading to potential health threats, time wasted on avoidable 
321 consultations, with the corresponding work absence and loss of productivity. 
322 Although some of these examples may appear unrelated to pharmacy, in many 
323 countries pharmacists are involved (e.g. in the execution and interpretation of 
324 diagnostic tests), This implies that if information systems were more intelligently 
325 planned, a test undertaken in any of these settings should immediately become 
326 associated with the patient ID, leading other healthcare professionals involved not to 
327 require their repetition, unless borderline values or other reasons for uncertainty were 
328 identified. However, there are good examples worldwide how these barriers are being 
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329 transposed. In New Zealand for example, there is an instituted program directly 
330 linking community pharmacies and GP practices so that information is shared and 
331 both professionals are constantly up-to-date with the way the patient is managing his 
332 therapy (45). In Portugal, a shared information system between all medical practices 
333 has been developing, where it is possible to continuously monitor the tests and 
334 treatments instituted, as well as episodes of hospital admission. The citizen is 
335 responsible for deciding who has access to his/hers information and it is expected that 
336 this will include pharmacists. In Flandres there is an electronic platform that allows 
337 pharmacists and GPs to share medical information like the vaccination status, 
338 medication overview, and population screening if applicable. The latest data from 
339 2018 indicate over 6.7 million inhabitants (from a total of 11.5 M in the country) have 
340 their data shared on this platform (46). 
341 Information transferred at discharge tends to be poor, as shown by a recent study 
342 where complete medication data was only available in 5% of individuals discharged 
343 (47). However, it has also been shown that simple interventions focusing on better 
344 information transfer, mostly across the healthcare interfaces, have positive impacts on 
345 patient safety. A meta-analysis has shown that single medication reconciliation at 
346 transitions of care, which are the most common interventions reduce medication 
347 discrepancies in 66% (48).
348 New ways of working are being discussed and tested worldwide and it seems today 
349 undisputable that working harder using the same hospital-centred model will not 
350 improve the lives of our community-dwelling citizens (49). Efficiency needs to arise 
351 from different delivery models, more centred on the communities, the mobility of 
352 individuals and their empowerment and willingness for self-management.
353 Refer-to-Pharmacy is an example of an electronic referral-system under development 
354 in the UK, through which hospital pharmacists refer patients directly to their 
355 community pharmacist for medication support (50). Another example from the UK 
356 are the one stop clinics have been emerging also for cardiovascular treatments (51), 
357 following the successful examples from oncology (52). The main idea behind these 
358 clinics is to increase and expedite access to preventive care and then to ensure an 
359 adequate onward referral is made so that care is fully integrated. For pharmacists it is 
360 obviously important to be part of this structure fully integrated in the primary care 
361 team and also being responsible for medicines’ timely access and for ensuring 
362 medicines optimisation.
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363 More recently, a national initiative in the UK has focused on the transfer of care 
364 around medicines following data whereby following electronic referral from hospital 
365 to community pharmacy, there  were statistically significant lower rates of 
366 readmissions amongst those that received a community pharmacist follow up 
367 consultation that those without a follow up consultation (53). In terms of 
368 multiprofessional collaboration, the role of technologies is extremely important, and 
369 there are only a few examples identified where the pharmacist has full read and write 
370 access to the patient medication record, namely in Valencia (54). Of course, this 
371 aspect is not only related to technology ability but also to law, data protection and 
372 ethics and frequently the arguments used to prevent full integration of information 
373 between all intervenient parties are related to confidentiality. Interestingly, there are 
374 recent cases where patient representative associations created fora to raise awareness 
375 about the need to use and share patient data (e.g. usemydata.org), whilst other created 
376 digital tools to collect information on medicines use and subsequently shared it with 
377 the European regulatory agency. This suggests that perhaps those claimed to need 
378 protection, are those who better understand the full benefits of information technology 
379 used securely. 
380
381 5 - Optimal Management of the condition 'closer to home'
382 The health care paradigm has progressively been shifting from a care centred on the 
383 treatment of illness to care directed at illness prevention. However, in many countries, 
384 this is still not fully achieved for many reasons, a frequently cited reason being 
385 finances, which are mainly directed at treatment rather than prevention. However, as 
386 systems evolve, it is expected that the care is provided as close as possible to the 
387 individual’s home. This will enable much more frequent monitoring with lower 
388 interference in the person’s daily life aligned with the theology of primary care. 
389 However, even within primary care there are many countries where systems are 
390 defragmented and the full potential of existing structures is not reached. A traditional 
391 dichotomy between public and private entities exists in many Beveridge countries and 
392 this extends to ensured and uninsured entities in Bismark models. This constitutes a 
393 major barrier mainly for community pharmacists aiming to supplement the services 
394 provided by others, in areas where there is an expressed need. Again, there are cases 
395 of success in some countries where pharmacist-led services have been remunerated 
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396 (National Health Service/insurance co-payment), which may be seen as recognition of 
397 value and need.      
398 5.a) Adherence of patients to treatment: 
399 Evidence-based medicine guides prescribing and it is universally recognised that the 
400 highest level of evidence arises from RCTs, systematic reviews and meta-analysis 
401 (55) (56) (57). However, in trials two basic assumptions are made: 1) that individuals 
402 included in the trial represent the person in front of you requiring therapy, which is 
403 not always the case recognising all clinical trials have strict inclusion and exclusion 
404 criteria; and that the patient takes the drug as prescribed, also known to be untrue. The 
405 first issue is dealt in papers looking at the efficacy/effectiveness gap (58), which have 
406 greatly contributed to raise the awareness on the need for real-world evidence, 
407 currently driving most of the observational studies being done in various areas (59). 
408 Others have shown that there are differences in the medicine use patterns of real-life 
409 patients, namely in primary adherence, in secondary adherence but also in persistence 
410 (60) (61). These issues, often forgotten, will greatly impact on the outcome of 
411 therapy, both in terms of stroke prevention but also on haemorrhagic events. 
412 In primary prevention, the communication terms used by health care professionals to 
413 describe medication are important as these may influence the perceived need. The use 
414 of the word therapy instead of treatment has been recently advocated by patient 
415 representatives and in fact the reason seems quite logical. If you refer to treatment, it 
416 implies the person is ill and is expecting recovery, therefore is likely to discontinue 
417 medication when asymptomatic. When the word therapy is used, this means that it 
418 may include preventive care, like it is the case of anticoagulants which mainly are 
419 used to prevent stroke, whereas other medications may be used to manage the 
420 eventually existing symptoms of disease.
421 There is extensive evidence on the impact of medication adherence in secondary 
422 cardiovascular prevention on Major Adverse Cerebral and Cardiovascular Events 
423 (MACCE) (62). The positive impact of treatment simplification has been 
424 demonstrated (63). However, complexity of treatment depends not only on the 
425 number of doses taken per day, but also on the pharmaceutical formulation (powder 
426 versus pills), need for dose adjustment and additional requirements (e.g. splitting 
427 pills; taking one pill every other day), and the total number of medicines. Treatment 
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428 simplification is already undertaken by hospital and community pharmacists, 
429 normally as a component of a broader service, namely medication reconciliation, 
430 medication review or certain forms of adherence enabling services. Medication 
431 adherence interventions should be tailored to the specific patient’s needs and also to 
432 the phase of the person-medication relationship (64). The NMS service for example is 
433 particularly suited to enhance medication adherence in the initial phase of treatment. 
434 The service is designed to have an initial consultation and a follow-up visit and the 
435 evaluation of this service has shown a 10% increase in adherence (40). However, the 
436 sustainability of the effects has yet to be demonstrated. Other interventions may be 
437 more useful during the implementation phase for instance, which may include simple 
438 interventions (e.g. reminder cards or dose-administration aids) (65) (66) and expand 
439 to complex interventions (67).
440 In the concept of care closer to home, patient empowerment is central. This implies 
441 raising health literacy of the population to provide them with the necessary means to 
442 manage their condition. A service recently developed in France consists of two or 
443 three interviews between pharmacists and patients over the course of one year, which 
444 aims to instruct patients on their anticoagulant medication (warfarin), to ensure 
445 patients understand the directions of use and know how to deal with side-effects and 
446 drug interactions (68). 
447 The role of the community pharmacist in the management of drug-drug interactions 
448 (DDIs) is also of utmost importance and it is an intervention that must precede any 
449 adherence enabling strategy developed. A study analysing over 250,000 prescriptions 
450 in community pharmacy identified DDIs in over 10% of them and highlighted 
451 warfarin as one of the two drugs classified as at highest risk for causing potentially 
452 serious interactions (the highest severity; class D). This is an area with enormous 
453 potential and with clear benefits for patient safety and better use of medical resources 
454 available, surely resulting on cost-savings (69). Interesting technological solutions in 
455 this area are being developed to help pharmacists in this role. The “Check for 
456 Medication Appropriateness” (CMA) is a system integrating clinical rules to identify 
457 four main types of high-risk situations involving medication use:  drug use in renal 
458 insufficiency, use of QTc interval prolonging drugs, use of drugs with a restricted 
459 indication or dosing and use of very severe drug-drug interactions. Early data from 
460 using this system highlighted anticoagulants as the drug class leading to more 
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461 frequent interventions, clearly confirming the need for additional monitoring systems 
462 and collaborative efforts in anticoagulation medication management in ambulatory 
463 care (70). 
464 In Belgium, drug dispensing data can be shared amongst pharmacists through the 
465 shared pharmaceutical file, enabling additional opportunities for detecting drug-drug 
466 interactions, including those acquired in other pharmacies (71).
467 Technology in general has enormous potential for the management of individuals at 
468 home these are used in an intelligent manner. In the UK for example, there are 
469 currently virtual clinics being developed so that patients discharged from hospital 
470 following a myocardial infraction are managed remotely (72). This includes having 
471 the ability to have access to laboratory and clinical data (e.g. blood pressure readings 
472 and LDL levels) entered periodically by the patient, but also access to patient reported 
473 experiences and outcomes (PREs and PROs), such as experienced side-effects and 
474 perceived quality of life. Another interesting example recently emerged in Belgium 
475 where a cloud based medication profile is made available for the patient to access 
476 using his ID card. The details are entered by the physician or the pharmacist but there 
477 the notion of a shared responsibility in this medication record. The “Personal Health 
478 Viewer” enables the patient to see his own detailed information, including medical 
479 reports, lab results, registration as organ donor, end-of-life decision, nursing files, 
480 among others. This system considers the citizen is the holder of all information, as 
481 foreseen by the current legislation, and as such enables the citizen to choose who can 
482 access his data (73).
483
484 6 - Secondary care for episodes of ill health 
485 When instances of the care pathway fail, eventually the patient may have a reason for 
486 admission to hospital.  In this phase, there are important roles for both community and 
487 hospital pharmacists, in sharing information about medication in both ways. This 
488 allows the pharmacists   to undertake medication reviews and optimisation of 
489 medicines.  Using the example of OAC, several studies have illustrated that 
490 inappropriate prescribing, monitoring, and administration of OAC occur frequently. 
491 Oral anticoagulants are often under dosed, inadequately monitored, contributing to 
492 increased risk for DRPs (74) (75) (76). 
493 Anti-coagulants have been identified among the top medication classes leading to 
494 hospital admissions, regardless of the investigated country (77) (78) (79). Some 
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495 studies have even evidenced the causality associated, highlighting warfarin as a 
496 “definite” responsible for GI bleeds (80). However, it has been shown that services 
497 like the integrated medicines management is effective in reducing the risk of hospital 
498 re-admissions, a service where pharmacists play a key role (81).
499 5-20% of hospital admissions are caused by medication misuse and that more than 
500 half of these are avoidable. Medication non-adherence is one of the areas for concern, 
501 as it is estimated that 11-22% of hospital admissions for exacerbations of chronic 
502 disease are a direct result of it (82). However, potential interventions in this area seem 
503 more indicated for pharmacists influencing ambulatory care. In fact, the hospital 
504 pharmacist has a key role in pharmacokinetics monitoring because it has been shown 
505 that the frequency of bleeding correlates most closely with the minimum steady state 
506 plasma drug concentration. This is illustrated in a study where edoxaban was 
507 administered 30 mg twice daily led to significantly more bleeding events than the 
508 same drug administered as 60 mg once daily (83). 
509 Although none of the RCTs leading to market entry of NOACs directly compared 
510 efficacy and safety of standard and low doses, there seems to be an overuse of the 
511 reduced dose in the absence of renal indication for dose adaption. This is an 
512 observation applicable to all NOACs, albeit more market in dabigatran, likely to 
513 result from the different mechanism of action (84).  In routine clinical practice, 
514 prescribed NOAC doses are often inconsistent with drug labelling. These prescribing 
515 patterns may be associated with worse safety with no benefit in effectiveness in 
516 patients with severe kidney disease and worse effectiveness with no benefit in safety 
517 in apixaban-treated patients with normal or mildly impaired renal function (34).
518
519 Some studies have even demonstrated that a proportion as high as 30% of patients 
520 were receiving a dose of dabigatran inappropriately low, after taking into account 
521 creatinine clearance, age and bleeding risk (85).
522 The predictors for dose reduction, other than dabigatran treatment, include advanced 
523 age, high CHA2DS2-VASc score, and high HAS-BLED score (86).
524 The role of the hospital pharmacist in medicines optimisation goes obviously beyond 
525 OAC and studies undertaken in Brazil have shown that even in venous 
526 thromboembolism prevention, there is wide room for improvement as around 40% of 
527 hospitalised patients were found to receive inappropriate treatment (87). 
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528 Dose adaptation in the presence of renal impairment is also a key role for hospital 
529 pharmacists. With the more recent introduction of NOACs, all of which are partially 
530 eliminated via the kidney, the assessment of kidney function is important to estimate 
531 their clearance and ensuring appropriate dosing. However, a study conducted in 
532 Denmark with the purpose to describe the severity of adverse medication incidents 
533 caused by oral anticoagulants in hospitals showed that all fatal and almost all serious 
534 adverse medication incidents were associated with the prescribing phase of the 
535 medication process. In addition, during admission and surgery, prescribing excess 
536 anticoagulant was the most frequent problem and, on the other side, during discharge, 
537 prescribing insufficient anticoagulant was the most frequent problem (88). As more 
538 drugs to improve patient outcomes enter the health care system, potential new 
539 interactions become apparent. These interactions can impact on a drug’s absorption, 
540 distribution, metabolism, excretion, or actual clinical effect.  Drugs with a narrow 
541 therapeutic range or low therapeutic index are more likely to be the objects for serious 
542 drug interactions and as pharmacists, monitoring and altering doses to mitigate is part 
543 of our everyday process in reviewing patients. A Swedish study investigating the role 
544 of computerized medical records showed that over one fifth of ADR induced hospital 
545 admissions resulted from drug-drug interactions (DDIs) and frequently associated 
546 with polypharmacy (89), hence possible to manage and prevent by pharmacists’ 
547 interventions. Another study in Bogota found that over 84% of hospitalized patients 
548 had one DDI, with the second more frequent involving anticoagulants (90). A 
549 systematic review additionally showed that NSAIDs were more commonly involved 
550 in DDIs leading to hospital admissions whereas warfarin was more frequently 
551 identified at emergencies or at outpatient hospital visits (91). This information could 
552 be important to better target the allocation of pharmacist workforce.
553 With initiatives aiming to reduce length of hospital stay, and with reports of 
554 approximately 60% of patients having three or more medicines changed during their 
555 hospital stay, the need to counsel patients on medicines at discharge but also the need 
556 to ensure adequate transfer around medicines has been communicated (92). Even 
557 when the patient uses the hospital as an unplanned admission, there have been 
558 initiatives emerging where patients are transferred home as soon as possible, while 
559 ensuring adequate hospital care is provided during a limited period of time until full 
560 recovery is achieved.  Domiciliary hospitalisation is a relatively new concept that is 
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561 now implemented in some countries, namely Australia, UK, Spain and Portugal, 
562 which fits this purpose (93).
563 Improving the transfer of information about medicines across all care settings would 
564 help to reduce incidents of avoidable harm to patients and contribute to a reduction 
565 avoidable medicines-related admissions and re-admissions to hospital.  In the UK, the 
566 continuity of patient care when transitioning from one healthcare setting to another is 
567 a national priority (94).
568 A recent systematic review highlighted how community pharmacists could help 
569 identify and rectify medication errors, thus providing a significant impact on 
570 improving outcomes (95).  In 2012, the Royal Pharmaceutical Society (RPS) issued 
571 professional guidance in its publication ‘Keeping patients safe when they transfer 
572 between care providers—getting the medicines right’  on the core principles that 
573 underpin the safe transfer of information related to medicines for a patient transferring 
574 between care providers in any setting (96).
575 Effective interventions for minimising medication interactions and keeping patients 
576 out of hospital have long been shown to be cost-effective, with the PINCER trial 
577 evidencing important reductions in medication misuse in various therapeutic areas, 
578 including antihypertensive medication. This study was conducted across a sample of 
579 72 GP practices and in this particular case evidenced a reduction in the long-term 
580 prescription of angiotensin converting enzyme (ACE) inhibitor or loop diuretics to 
581 those 75 years or older without assessment of urea and electrolytes in the preceding 
582 15 months (97). Currently, with the recent investment in pharmacists working 
583 collaborative within GP practices, surely the impact of such initiatives will see a 
584 quick boost.  
585
586 7 - Tertiary care and End of Life care – domiciliary support 
587 Prescribing of medicines for older people who live in nursing homes is a very 
588 common intervention.  Prescribing is one of the most common medical interventions 
589 experienced by older people resident in nursing homes (98).  
590 Residents are often the frailest old and take up to four times as many medications than 
591 their age-matched community-dwelling nonfragile older counterparts in addition to 
592 age-related changes in pharmacokinetics and pharmacodynamics, nursing-home 
593 residents are at high risk of adverse drug events (99).
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594 The US experience of using consultant pharmacists to carry out medication review 
595 represents one practice model that has been in place for some time. Indeed, this role is 
596 mandatory in all US nursing homes which receive funding from major federal 
597 government health programmes (100).
598 A number of studies have been conducted in Australia involving pharmacists either as 
599 the main professional delivering the intervention, or as part of a multidisciplinary 
600 team. Roberts and colleagues implemented a programme which focussed on 
601 establishing professional relationships between pharmacists and nursing home staff, 
602 educating nurses on common issues in geriatric pharmacotherapy, and medication 
603 reviews prepared by the pharmacists. These reviews were considered by a geriatrician 
604 and showed a reduction in the number of prescribed and administered drugs, some 
605 reductions in prescribing costs (101).
606 Deprescribing in general has become quite popular as a multidisciplinary team 
607 intervention, arising as a counter response to the rise of polypharmacy. More recently, 
608 other initiatives, such as “Choosing wisely” highlight not only the notion of evidence-
609 based medicine but rationality (and sometimes also rationing) related to decision 
610 making. A good example is the paradox evidenced in a study that has demonstrated 
611 that in the last year of life, the number of medications prescribed rises, not only as a 
612 result of symptomatic medications but also as result of using long-term preventive 
613 treatments, for which the benefit is obviously intangible at this stage of life (102). 
614 One quite common example of therapy within this category is lipid—lowering 
615 medications, reported to be used by nearly 10% of individuals in their last month of 
616 life (103).    
617
618 Discussion
619 In most countries worldwide, health care system is developed in siloed structures, 
620 perhaps ignoring that an individual can move from one to the other care site and 
621 receive duplicate or contradictory care. The development of a collaborative pathway 
622 is essential to provide better care in a holistic manner. Taking some examples from 
623 services marketing, the idea transmitted in the 4C’s, can perfectly be adapted to health 
624 care. Today there is vast information available on the use of healthcare resources, 
625 which enables us to analyse past events and time-trends and use that information for 
626 clairvoyance, ie, anticipate the needs of the population in real time. The WHO has 
627 long stated that if nothing is reversed in the way people live (including lifestyle 
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628 options and environmental factors), chronic obstructive pulmonary disease will be the 
629 third leading cause of death in 2030. This is one example, but there are many others 
630 that may be used to anticipate future needs of our society; obesity in the industrialised 
631 countries is also one important factor which directly contributes to the burden of 
632 cardiovascular disease. If we anticipate we will have rising burden of obesity, we 
633 need to develop effective collaboration across sectors that may have an impact on 
634 obesity and this is the principle of Policy in all policies. If we simply focus on 
635 healthcare treatment, ignoring the role of preventive care, perhaps all investment will 
636 be directed to the structure and workforce needed to provide more bariatric surgeries. 
637 However, if we think broader, there will be a role to play also in the education, 
638 environment, trade and health sectors. Schools must be places incentivising sports and 
639 healthy eating, there must be equal conditions for children and adults of all socio 
640 economic strata to exercise, and economic capacity cannot be barriers to healthy 
641 eating. Within the health sector, the collaboration also needs to be organised to 
642 accompany the person’s lifecycle. The health champions’ programme in the UK is a 
643 public health initiative set up to invest in prevention, but seems to focus mainly in 
644 adult individuals, losing its full potential. Pharmacists and allied HCPs must move out 
645 of their comfort zone and engage with local schools, as they are currently doing to 
646 administer HPV vaccines. But, there is more to preventive care. The role of 
647 technologies is also important and while apple and other giants are developing 
648 applications to count steps and monitor blood pressure, healthcare seems to be the 
649 passive recipient, not being able to incorporate technology as a means to 
650 communicate with healthy individuals and contribute to disease prevention. Why not 
651 developing a public health app, through which the individual is motivated with 
652 gaming and other powerful tools to engage into healthy living? Also, this app should 
653 then be able to collect data that can intelligently be used to provide information to a 
654 health care hub, indicating if the individual should seek preventive care and favour 
655 integration of primary care providers; in other phases, perhaps direct him to urgent or 
656 hospital care and in the last instance to palliative care. This system must be powerful 
657 enough to break the silos and connect the pathway horizontally to go along the 
658 individual’s lifecycle. Most workspaces are currently physically set up in a way that 
659 does not favour collaboration. This needs urgent solving and surely architects and 
660 engineers can come up with solutions for health care equally functional as they have 
661 been able to do for other sectors. Once an efficient pathway is established, then it 
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662 should be customized and national upscaling will follow. Finally, for people to be 
663 able to use it efficiently, communication about its functions must be made freely 
664 available to all, including the providers and the public. Communication with the 
665 public is often not maximised in healthcare and again in this area, experts in the filed 
666 should be sought so that flexible solutions exist to reach the low literate, the media 
667 excluded but also the highly educated.
668 This position paper tried to set the scene by identifying areas along the patient 
669 pathway where pharmacists are present, although their full potential is currently 
670 underused. Next steps will need to focus on the identification of effective ways to 
671 make pharmacists useful and efficient resources for integrated cardiovascular care.    
672
673 Limitations: Literature review was mostly narrative, to support some of the thoughts 
674 and to foster additional idea exchange. We did not aim for a systematic review, so 
675 there is surely relevant literature missing. This position paper results from the 
676 personal perspectives of a group of individuals with shared common interests, namely 
677 the fact that all authors are pharmacists and are therefore likely to have strong beliefs 
678 in the power of this workforce. Nonetheless, we have tried to support the views 
679 conveyed with evidence generated from various countries.
680
681 Conclusion:
682 Pharmacists are located in various steps across the patient care pathway, close to the 
683 community, in hospitals and in tertiary care, with no barriers to access driven by the 
684 need to book or pay for appointments, and in some areas being the only health service 
685 in that area. We have highlighted various areas where pharmacists seem to be an 
686 untapped resource for the implementation of a person-centred care pathway in the 
687 area of anticoagulation. 
688
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Figure 1: Patient care pathway in cardiovascular disease 
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